Creative Commons source reading · Clinical neurodiagnostics
Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes.
Corinne Quadalti; Giovanna Calandra-Buonaura; Simone Baiardi; Andrea Mastrangelo; Marcello Rossi; Corrado Zenesini; Giulia Giannini; Niccolò Candelise; Luisa Sambati; Barbara Polischi; Giuseppe Plazzi; Sabina Capellari; Pietro Cortelli; Piero Parchi
Originally published in NPJ Parkinson's disease · 2021-10-11
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Neurofilament light chain (NfL) and α-synuclein oligomeric seeds (α-syn-s) are promising biomarkers for patients with parkinsonism. We assessed their performance in discriminating Parkinson disease (PD) from atypical parkinsonisms (APDs) and evaluated the association between NfL levels and clinical measures of disease severity. We measured NfL in cerebrospinal fluid (CSF) and/or plasma by immunoassays and α-syn-s in CSF by real-time quaking-induced conversion (RT-QuIC) in patients with PD (n = 153), multiple system atrophy (MSA) (n = 80), progressive supranuclear palsy/cortico-basal syndrome (PSP/CBS) (n = 58), dementia with Lewy bodies (n = 64), isolated REM-sleep behaviour disorder (n = 19), and isolated autonomic failure (n = 30). Measures of disease severity included disease duration, UPDRS-III score, Hoehn and Yahr stage, orthostatic hypotension, MMSE score, and CSF amyloid-beta profile. Both CSF NfL (cNfL) and plasma NfL (pNfL) levels were markedly elevated in APDs, and allowed differentiation with PD (vs. APDs, cNfL AUC 0.96; pNfL AUC 0.95; vs. MSA cNfL AUC 0.99; pNfL AUC 0.97; vs. PSP/CBS cNfL AUC 0.94; pNfL AUC 0.94).
Discussion
Here we reported the results of a comprehensive evaluation of the diagnostic and prognostic value of NfL and α-syn seeding activity, including the comparison between cNfL and pNfL performance, and the analysis of the added value of a combined CSF analysis of NfL and α-syn seeding activity, in a large cohort of patients with parkinsonism and related prodromal syndromes.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
